BRIEF: CStone raises $134 million in share placement at 7% discount
Drugmaker CStone Pharmaceuticals (2616.HK) announced on Wednesday it will place 118 million new shares at HK$8.97 each, representing about 7.4% of its enlarged share capital. The placement price reflects a…
CSPC Pharma taps R&D superstar in quest for new breakout drugs
Liu Yongjun’s drug commercialization experience and ties to multinational firms are urgently needed for his new employer’s ongoing transformation Key Takeaways: CSPC Pharma’s new R&D head Liu Yongjun engineered the…
Stock disconnect triggers investor exodus from CStone Pharma
The share price fell nearly 40% in a week after the drugs company was dropped from a scheme allowing mainland investors to trade Hong Kong-listed stocks Key Takeaways: CEO Jason…
HBM gets health boost from drug licensing deals
The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer Key Takeaways: Nona Biosciences, a subsidiary of…
FAST NEWS: CStone licenses PD-1 cancer drug to 3SBio for China
The latest: CStone Pharmaceuticals (2616.HK) announced Wednesday that it has exclusively licensed Shenyang Sunshine Pharmaceutical, a subsidiary of 3SBio Inc. (1530.HK), to develop, register, manufacture and commercialize its anti-PD-1 antibody Nofazinlimab…
FAST NEWS: CStone says CEO to boost company holdings
The latest: CStone Pharmaceuticals (2616.HK) on Tuesday announced that its CEO Jason Yang plans to buy up to HK$5 million ($640,000) worth of the company’s shares in the open market over the…
CStone breaks up with drugs partner as U.S. rollout stalls
CStone Pharmaceuticals has pulled out of a licensing deal with EQRx for two innovative cancer drugs but holds onto money already received from its partner Key Takeaways: The companies parted…
Recent Articles
RELATED ARTICLES
-
Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
- Jacobio Pharma poised to turn a profit from precision cancer drugs
-
BRIEF: Voicecomm raises $40 million via share placement at 20% discount
2495.HK
-
BRIEF: Time Interconnect raises $209 million in share placement at 15% discount
1729.HK
- Ming Yu seeks a share of the drug sector limelight
- BRIEF: CANbridge raises $26 million in share sale to WuXi Bio at 14.7% discount
